AstraZeneca (LON:AZN) Given Sell Rating at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “sell” rating reiterated by research analysts at Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Tuesday,London Stock Exchange reports. They presently have a £115 price objective on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential downside of 14.40% from the company’s current price.

A number of other research analysts also recently issued reports on the company. Jefferies Financial Group reissued a “buy” rating and issued a £180 price target on shares of AstraZeneca in a report on Wednesday, May 13th. Citigroup upped their target price on AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a research note on Friday, April 10th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and an average price target of £153.33.

AstraZeneca Trading Down 2.7%

Shares of LON:AZN opened at £134.34 on Tuesday. AstraZeneca has a 12-month low of £101.03 and a 12-month high of £157.32. The company has a market capitalization of £208.34 billion, a PE ratio of 20.23, a PEG ratio of 0.86 and a beta of 0.22. The business has a 50 day moving average of £142.31 and a two-hundred day moving average of £141.42. The company has a current ratio of 0.91, a quick ratio of 0.59 and a debt-to-equity ratio of 71.66.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.